A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

Study Purpose

The primary objective of this study is to evaluate the long-term safety of apremilast in participants 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic arthritis that have completed Study 20190530 or Study 20190529.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 5 Years - 18 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Informed consent / assent obtained.
  • - Must have completed Week 52 on treatment on core study.
  • - Age and sex specific body mass index (BMI) no lower in range than the 5th percentile on Centers for Disease Control (CDC growth chart) - Willing to adhere to study visit schedule and protocol requirements.
  • - Must have acceptable benefit/risk for continued treatment with apremilast.

Exclusion Criteria:

  • - Answer "yes" to any question on C-SSRS at Week 52 visit of core study.
  • - Scheduled surgery or other interventions that would interrupt study participation.
  • - Female participants of childbearing potential unwilling to use protocol specified method of contraception during treatment and for 30 days after last dose.
  • - Female participants planning to become pregnant while on study through 30 days after last dose.
  • - Female participants of childbearing potential with positive pregnancy test at Week 0.
  • - Known sensitivity to any products to be administered during dosing.
- Not likely to be available to complete all protocol-required study visits

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05767047
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Amgen
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

MD
Principal Investigator Affiliation Amgen
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Greece, Israel, Spain, Turkey
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Behçet's Disease, Juvenile Psoriatic Arthritis
Study Website: View Trial Website
Arms & Interventions

Arms

Experimental: Apremilast

Participants with a weight between ≥ 12 kg to < 20 kg will receive apremilast 10 mg BID (twice a day), participants with a weight between ≥ 20 kg to < 50 kg will receive 20 mg BID, and participants with a weight ≥ 50 kg will receive apremilast 30 mg BID.

Interventions

Drug: - Apremilast

Oral tablets or liquid suspension

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Thessaloniki, Greece

Status

Recruiting

Address

General Hospital of Thessaloniki Ippokrateio

Thessaloniki, , 54642

Meir Medical Center, Kfar Saba, Israel

Status

Recruiting

Address

Meir Medical Center

Kfar Saba, , 4428164

Hospital Universitari i Politecnic La Fe, Valencia, Comunidad Valenciana, Spain

Status

Recruiting

Address

Hospital Universitari i Politecnic La Fe

Valencia, Comunidad Valenciana, 46026

Hospital Universitario Ramon y Cajal, Madrid, Spain

Status

Recruiting

Address

Hospital Universitario Ramon y Cajal

Madrid, , 28034

Umraniye Egitim ve Arastirma Hastanesi, Istanbul, Turkey

Status

Recruiting

Address

Umraniye Egitim ve Arastirma Hastanesi

Istanbul, , 34764

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.